Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images

Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Nominations for the Broermann Medical Innovation Award 2026 now open5.9.2025 09:13:31 CEST | Press release
With a million euros, it is one of the world’s most highly endowed awards for medical research
Europe’s Digital Paradox: Citizens Feel Abandoned by Companies and Authorities on Cybersecurity - yet They also Don’t Protect Themselves4.9.2025 10:00:00 CEST | Press release
A representative study of 14,000 Europeans highlights citizens’ concerns about digital threats and data sovereignty. Major concerns include identity theft, financial uncertainty and the effects of cyberattacks on democracy. While citizens recognize cybersecurity deficiencies and have little trust in companies and authorities, they do not take personal responsibility for their own protection.
Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors4.9.2025 10:00:00 CEST | Press release
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector. Grünenthal PRO will expand its capacity for final assembly of SHL autoinjectors by installing additional assembly lines in its Origgio, Italy facility in 2026. These new pre-validated lines for Molly® 1.0 and 2.25 mL autoinjector platform will enhance speed-to-market for pharma and biotech companies, building on Grünenthal’s 10 year-experience in SHL autoinjector assembly services. In parallel, SHL customers will benefit from access to Grünenthal PRO’s established expertise and capacity in delivering high quality, reliable contract manufacturing services. “Speed-to-mar
From Grid Load to Revenue Stream: PLAN-B NET ZERO Makes the Energy Transition Economically Successful3.9.2025 11:44:39 CEST | Press release
Berlin, Berlin-based GreenTech startup PLAN-B NET ZERO BESS GmbH, a subsidiary of PLAN-B NET ZERO AG specialising in innovative energy storage solutions, demonstrates how its battery energy storage systems (BESS) enable businesses and private households to profit directly from the growing imbalance between very low and very high prices on the electricity exchange (EEX).
Seeding The Future Foundation, Institute of Food Technologists, and Welthungerhilfe Announce Evolution of the Seeding The Future Global Food System Challenge2.9.2025 14:12:44 CEST | Press release
(Plymouth, Minnesota; Chicago, Illinois; Bonn, Germany) — The Seeding The Future Foundation (STF), the Institute of Food Technologists (IFT), and Welthungerhilfe (WHH) today announced the next chapter of the Seeding The Future Global Food System Challenge (GFSC). With the conclusion of its fourth cycle, operations will transition from IFT to WHH, an international leader in food systems transformation and the fight against hunger in the Global South. Launched by STF in 2021 and hosted by IFT, the Challenge has become a premier platform for advancing breakthrough innovations. Over four years, it has drawn more than 4,000 applications from 97 countries, awarding $1 million annually to visionary teams tackling urgent food system challenges. The program has accelerated solutions that improve food security, reduce environmental impact, and build resilience in vulnerable communities. “We are incredibly proud of what the Challenge has achieved and the vital role we played in helping visionary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom